Please discuss recent analyses from the CLEAR study, evaluating lenvatinib + pembro in frontline advanced RCC. Efficacy by baseline tumor size (Grunwald, et al. ASCO GU 2024. Abstract 364) Biomarker analysis (Motzer et al. ASCO 2024 Abstract 4504) Network meta-analysis– len + pembro vs other 1L treatments in advanced RCC (Grunwald, et al. ASCO GU 2024. Abstract 482)